What is a stock summary page? Click here for an overview.
Business Description
Zevra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US4884451075
Compare
Compare
Traded in other countries / regions
ZVRA.USA1GDA.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2015-04-16Description
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.15 | |||||
| Equity-to-Asset | 0.22 | |||||
| Debt-to-Equity | 1.52 | |||||
| Debt-to-EBITDA | -0.79 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -3.14 | |||||
| Beneish M-Score | -3.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -19 | |||||
| 3-Year EBITDA Growth Rate | -84 | |||||
| 3-Year EPS without NRI Growth Rate | -10.5 | |||||
| 3-Year Book Growth Rate | -41.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 117.31 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.77 | |||||
| 9-Day RSI | 51.26 | |||||
| 14-Day RSI | 51.22 | |||||
| 3-1 Month Momentum % | -9.54 | |||||
| 6-1 Month Momentum % | -4.71 | |||||
| 12-1 Month Momentum % | 31.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.53 | |||||
| Quick Ratio | 2.47 | |||||
| Cash Ratio | 2.04 | |||||
| Days Inventory | 96.95 | |||||
| Days Sales Outstanding | 158.72 | |||||
| Days Payable | 665.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.3 | |||||
| Shareholder Yield % | -21.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.59 | |||||
| Operating Margin % | -368.47 | |||||
| Net Margin % | -446.85 | |||||
| FCF Margin % | -295.04 | |||||
| ROE % | -208.85 | |||||
| ROA % | -62.98 | |||||
| ROIC % | -97.44 | |||||
| 3-Year ROIIC % | -134.26 | |||||
| ROC (Joel Greenblatt) % | -5642.65 | |||||
| ROCE % | -65.18 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 16.4 | |||||
| PB Ratio | 10.82 | |||||
| EV-to-EBIT | -5.12 | |||||
| EV-to-Forward-EBIT | -2.97 | |||||
| EV-to-EBITDA | -5.55 | |||||
| EV-to-Forward-EBITDA | -14.01 | |||||
| EV-to-Revenue | 17.97 | |||||
| EV-to-Forward-Revenue | 4.94 | |||||
| EV-to-FCF | -6.09 | |||||
| Price-to-GF-Value | 0.89 | |||||
| Earnings Yield (Greenblatt) % | -19.53 | |||||
| FCF Yield % | -16.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZVRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zevra Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 23.612 | ||
| EPS (TTM) ($) | -2.26 | ||
| Beta | 0.68 | ||
| 3-Year Sharpe Ratio | 0.35 | ||
| 3-Year Sortino Ratio | 0.64 | ||
| Volatility % | 54.44 | ||
| 14-Day RSI | 51.22 | ||
| 14-Day ATR ($) | 0.400074 | ||
| 20-Day SMA ($) | 7.854 | ||
| 12-1 Month Momentum % | 31.51 | ||
| 52-Week Range ($) | 4.2 - 9.76 | ||
| Shares Outstanding (Mil) | 54.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zevra Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zevra Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zevra Therapeutics Inc Frequently Asked Questions
What is Zevra Therapeutics Inc(ZVRA)'s stock price today?
The current price of ZVRA is $7.99. The 52 week high of ZVRA is $9.76 and 52 week low is $4.20.
When is next earnings date of Zevra Therapeutics Inc(ZVRA)?
The next earnings date of Zevra Therapeutics Inc(ZVRA) is 2025-05-08 Est..
Does Zevra Therapeutics Inc(ZVRA) pay dividends? If so, how much?
Zevra Therapeutics Inc(ZVRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers